Physicians are trained to recognize what we know and, perhaps more importantly, what we do not know. We take a set of clinical findings, develop a differential diagnosis, gather more information, and work toward a treatment plan.

I assumed that same discipline would help me navigate the commercial development of a medical device. It did, but not nearly as much as I expected.

After decades as an anesthesiologist, I co-founded a company to develop a medical device based on a problem I had encountered repeatedly in clinical practice. I understood the clinical problem. What I did not understand was the extraordinary number of interconnected steps required to turn an idea into a product that might someday reach a patient.

There was no roadmap sitting on my desk. I wish there had been.

Over the ensuing years, I have had to learn about prototype development, intellectual property, FDA regulation, clinical validation, manufacturing, company structure, founder equity, government grants, and fundraising. Each subject has its own experts, terminology, costs, and decision points. More importantly, none exists independently of the others.

That is the lesson I would most like to pass on to other physicians considering the same journey: Having a good idea is only the beginning. Before spending substantial time and money, understand the pathway that lies ahead.

The steps do not come one at a time

One of my earliest misconceptions was that medical-device development would proceed sequentially: develop the device, patent it, test it, obtain regulatory clearance, manufacture it, and then sell it. The reality is far less orderly.

Engineering decisions may affect the FDA regulatory pathway. The anticipated regulatory pathway affects what investors are willing to fund. Manufacturing choices affect design. Clinical validation may uncover the need for additional engineering. Intellectual-property decisions may need to be made before the commercial strategy is settled.

And the company itself matters. A first-time founder may not initially appreciate why intellectual property should have a clean chain of title, why founder agreements should be in writing, why equity and dilution need to be discussed early, or why the choice between an LLC and a corporation may eventually matter to investors.

These are not glamorous parts of innovation. But correcting them later can be considerably more expensive and disruptive than addressing them properly at the beginning.

I learned that innovation is not a straight line. It is a collection of interdependent decisions, and decisions made in one area can create consequences somewhere else months or years later.

A patent is a milestone, not a destination

Receiving an issued U.S. patent felt significant, and it was. Years of work had resulted in an issued patent protecting important aspects of the invention.

But a patent does not tell you whether a device will work clinically. It does not determine how the FDA will classify it. It does not manufacture the product, establish a quality system, validate the device, or persuade someone to buy it.

And a U.S. patent protects an invention only in the United States. There is no single “world patent.” International protection requires additional decisions about where protection is commercially important and whether the potential market justifies the expense. For a physician accustomed to medicine, where anatomy and physiology do not change at national borders, discovering how geographically fragmented intellectual property and regulatory systems can be is an education in itself.

None of this means standards should be lowered. Medical devices should be rigorously evaluated and manufactured. Patient safety must remain the priority. But physician-inventors should understand these realities before, not after, they begin committing substantial resources.

The money problem begins long before there is a product to sell

Almost every step costs money. Better prototypes cost money. Patent attorneys cost money. Regulatory advice costs money. Testing costs money. Manufacturing preparation costs money. Corporate attorneys cost money.

And frequently, the next source of funding wants to see the result of the work that the funding itself is needed to accomplish. Investors understandably want regulatory clarity, evidence of clinical interest, a defensible intellectual-property position, a credible manufacturing strategy, and some understanding of unit economics. Obtaining those things requires capital.

That creates one of the central challenges for early medical-device companies: How do you finance the evidence required to convince someone to finance the company? There is no single answer.

Funding may come from founders, friends and family, angel investors, physicians, family offices, strategic partners, government grants, or venture capital. Each evaluates the opportunity differently.

I also learned that the same truthful story must be told differently depending on the audience. Clinicians want to know whether the device solves a meaningful clinical problem. Engineers ask whether it can reliably be built. Regulators consider risk. Investors evaluate whether the opportunity can generate an appropriate return.

The invention has not changed. The questions surrounding it have.

Not every worthwhile medical device needs to become a unicorn

This may be one of the more important lessons I have learned. Venture capital has a particular economic model. Venture funds need some investments to produce very large returns, so they understandably search for companies capable of extraordinary growth.

But medicine contains many problems worth solving that may never produce a billion-dollar company. A device may reduce clinician burden, make a procedure easier, decrease the likelihood of an error, or improve patient care while still supporting a viable business, without ever becoming the next enormous medical-technology company.

That does not make the problem medically unimportant. And it does not make the solution commercially unworthy. It may simply mean that venture capital is not the appropriate source of financing. We need sources of capital capable of recognizing the difference between a poor business and a good medical product whose financial opportunity happens to be more modest than the traditional venture-capital model demands.

The people who help you keep going

There is also a personal cost that does not appear on a development timeline. The founder carries the project continuously: the next prototype, regulatory question, test, and source of funding. Advisors, collaborators, and investors may care deeply about the project, but they have their own careers, families, and responsibilities. They cannot be expected to feel precisely the same urgency.

One of the more difficult thoughts is that a potentially useful device might fail not because it did not work, but because it could not survive the journey required to prove its value. That makes the people you encounter along the way particularly important.

I have met individuals who have given their time simply because they wanted to help. They have challenged assumptions, reviewed presentations, introduced me to people I never could have reached on my own, and explained things that were completely unfamiliar to me. Some have opened doors. Others have simply provided encouragement at exactly the right moment.

Friends also react differently. Some quite reasonably wonder why anyone would subject themselves to this process. Others understand why you continue and offer an introduction, a telephone call, a thoughtful question, or candid advice.

Not all early capital arrives as a check. Organizations that support entrepreneurs can be particularly valuable. My experience with TEDCO, Maryland’s technology-development organization, for example, has shown me the importance of having people who understand both the entrepreneurial process and how unfamiliar that process can be to someone entering it from another profession. The difficulty is finding the right people early enough.

What I wish had existed when I started

If I could change one thing for the next physician with an idea for a medical device, it would not be to lower the standards. A device intended for patients should have to demonstrate that it works. It should be appropriately regulated. It should be manufactured correctly. Its claims should withstand scrutiny.

What I would change is the navigability of the process. Imagine if a physician-inventor could begin with a practical roadmap showing:

• How to determine whether an idea is worth pursuing before spending heavily on it
• When and how to protect intellectual property
• How to structure the company and founder relationships properly from the beginning
• When to engage the FDA and how regulatory classification affects everything downstream
• What level of prototype is needed at each stage
• When simulation, bench testing, cadaveric work, or clinical validation becomes appropriate
• When to begin thinking about design for manufacturing and quality systems
• What realistic costs accompany each stage
• Which funding sources make sense at different points in development
• Which decisions are difficult or expensive to reverse later

And imagine if that roadmap connected founders to vetted patent attorneys, regulatory specialists, engineers, manufacturers, testing laboratories, grant programs, mentors, and investors, with reasonable transparency about costs and potential conflicts. Such a roadmap would not guarantee that an invention succeeds.

Nor should it.

Most ideas will encounter technical, clinical, or commercial obstacles, and some should stop. Knowing when to stop is part of responsible innovation too. But failure should occur because the device did not solve the problem, could not be made safe, could not be manufactured economically, or did not provide sufficient value, not because a physician-inventor didn’t know which question to ask or whom to ask.

The next physician with an idea

I have no regrets about taking this journey. I have learned an enormous amount, met remarkable people, and become even more convinced that clinicians have an important role in medical innovation.

They stand at the bedside, in the operating room, in the emergency department, and in the clinic. They see small problems repeatedly. Occasionally, one of them thinks: There has to be a better way to do this.

Sometimes there is.

We should want that physician to explore the idea. We should also tell that physician what comes next.

The pathway from clinical insight to medical product must remain rigorous. It does not need to remain mysterious. An issued patent may mark the end of one difficult chapter.

For many physician-inventors, it is only the beginning.

Michael Peck is a retired anesthesiologist with more than 40 years of clinical experience across academic and private practice medicine. He formerly served as an assistant professor at the George Washington University and as co-director of neuroanesthesiology, and he has lectured nationally and internationally on anesthesia and perioperative care.

His work has long centered on airway management, patient safety, and medical innovation, including the development of novel airway devices and digital tools built to support clinicians during critical events. His research and writing span neuroanesthesiology, airway complications, cerebral blood flow, and postoperative care, with work appearing in Anesthesia and Analgesia, Anesthesiology, and the Canadian Journal of Anesthesia, along with contributions to textbooks and board review series.

He is the co-developer of Code Runner Pro, a mobile application focused on improving adherence to ACLS and PALS protocols during resuscitations. His interests include medical education, simulation, clinical decision-making under stress, and the intersection of technology and patient care. He shares updates on LinkedIn.